Drug Development

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

As NEXGEL prepares for a key investor conference, it faces a crucial test: convincing the market its advanced hydrogel tech can overcome recent financial hurdles.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.

Scispot's Series A targets the messy 'coordination gap' in labs. It's a bet that before we get self-driving labs, we must first fix the data pipes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

As CEO Reshma Kewalramani takes the stage, investors will look for clues on how Vertex plans to pivot from CF dominance to a multi-franchise powerhouse.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

As its CEO heads to a top investor conference, Zealand Pharma leverages AI and novel peptides to challenge giants in the multi-billion-dollar obesity market.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Montara Therapeutics' new MJFF grant isn't just about Parkinson's. It's a bet on a 'BrainOnly' platform that could unlock a new era for CNS therapies.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.